Physician profile
David G Smith
NPI 1871584052
$932.51
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $38.90 · 2021: $139 · 2022: $280 · 2023: $256 · 2024: $66.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $322.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.37 | 2019-2023 | |
| Abbvie INC. | $81.61 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $71.22 | 2022-2023 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $59.11 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Sunovion Pharmaceuticals INC. | $51.92 | 2019 | |
| Shockwave Medical, INC | $46.76 | 2021-2022 | |
| Genentech USA, INC. | $38.00 | 2019 | |
| Mylan Specialty L.P. | $36.65 | 2022-2024 | Yupelri |
| Insmed, INC. | $33.22 | 2023-2024 | Arikayce |
| Inari Medical, INC. | $32.62 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $27.47 | 2022 | |
| Amgen INC. | $27.22 | 2022-2024 | Tezspire |
| Astrazeneca Pharmaceuticals Lp | $26.72 | 2019-2021 | |
| La Jolla Pharmaceutical Company | $25.09 | 2021 | |
| Abbott Laboratories | $24.09 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $21.88 | 2022 | |
| Philips North America LLC | $21.76 | 2020 | |
| Ambu INC. | $21.73 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.72 | 2021 | |
| Mayne Pharma Commercial LLC | $19.58 | 2021 | |
| Boston Scientific Corporation | $18.88 | 2023 | Exalt Model D |
| Chiesi USA, INC. | $17.14 | 2020 | |
| Grifols USA, LLC | $15.58 | 2022 | |
| Merck Sharp & Dohme LLC | $14.09 | 2022 | |
| Novo Nordisk INC | $13.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.